摘要
为进一步规范我国肝癌临床诊疗行为,中国临床肿瘤学会基于循证医学证据、专家意见等于2022年更新并发布了《原发性肝癌诊疗指南(2022年版)》,笔者针对新版指南中对于肝癌内科治疗策略更新进行研读。
To further standardize the clinical diagnosis and treatment behavior of hepatocellular carcinoma,based on evidence-based medical evidence and expert opinion,Chinese Society of Clinical Oncology updated and published guideline of hepatocellular carcinoma.In this paper,the new guideline on the updating of medical treatment strategies for hepatocellular carcinoma was studied.
作者
王晓昊
李虎
张露
蔡大川
WANG Xiaohao;LI Hu;ZHANG Lu;CAI Dachuan(Department of Infectious Diseases,The Second Affiliated Hospital,Chongqing Medical University,Chongqing 401336,P.R.China;Key Laboratory of Molecular Biology for Infectious Diseases,Ministry of Education,Chongqing 401336,P.R.China;Institute for Viral Hepatitis,Chongqing Medical University,Chongqing 401336,P.R.China)
出处
《中国普外基础与临床杂志》
CAS
2023年第4期403-407,共5页
Chinese Journal of Bases and Clinics In General Surgery
基金
重庆市科卫联合医学科研项目(项目编号:2022ZDXM001)
重庆市卫生健康委医学科研项目(项目编号:2022WSJK054)。
关键词
肝细胞癌
指南
治疗
研读
hepatocellular carcinoma
guideline
treatment
study
